Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

Published byΦώτιος Αρβανίτης Modified over 5 years ago

Similar presentations

Presentation on theme: "A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing."— Presentation transcript:

1 A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing Liao, MD, Weiye Deng, MD, Cai Xu, MD, Ritsuko Komaki, MD, Mariela Blum, MD, Wayne L. Hofstetter, MD, Linus Ho, MD, PhD, Steven H. Lin, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 6, Pages (June 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Identification of included and excluded patients with esophageal cancer receiving chemoradiotherapy (CRT). AC, adenocarcinoma; SCC, squamous cell carcinoma; PET, positron emission tomography. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Disease-free survival and overall survival of the induction chemotherapy (IC) group versus the non-IC group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Disease-free survival and overall survival of the high-risk group versus the low-risk group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Disease-free survival of the induction chemotherapy (IC) group versus the non-IC group in different risk groups before and after propensity score matching. (A and B) High-risk group. (C and D) Low-risk group. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplemental Data 3 Figure 1. Overall survival curves of IC group versus non-IC group in different risk group before and after propensity score-matching (high-risk: A and B; low-risk: C and D). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

7 Supplemental Data 4 Figure 2. Survival curves of IC group versus non-IC group in different risk group in patients with adenocarcinoma (high-risk: A and B; low-risk: C and D). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing."

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer  Mian Xi, MD, Zhongxing.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed.

Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed.
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus  Yang Zhao, MD, ZhiJun Dai,
Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K

Jennifer C. Ho, MD, Quynh-Nhu Nguyen, MD, Heng Li, PhD, Pamela K
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.
Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer  Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation 

Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation 
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.

Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,

Similar presentations

Ads by Google